FloraWorks announced results of study demonstrating sleep benefits of its flagship CBN ingredient

Photo © iStockphoto.com/Camrocker

FloraWorks (Portland, OR) has announced the results of a study conducted by Radicle Science that demonstrates the sleep support benefits of its TruCBN cannabinol (CBN) ingredient. In the study, 1020 volunteers were randomly assigned to receive 4 mg of melatonin, placebo, 25 mg of TruCDN, 50 mg of TruCBN, and 100 mg of TruCBN nightly for six weeks. Subjects took one softgel prior to bedtime, and sleep improvements were measured using the PROMIS Sleep Disturbance 8a score survey. At baseline 66.6% of subjects experienced mild to moderate sleep disturbance and 90% have reported suffering from stress.

Results showed that there was a significant difference in the rate of mean PROMIS Sleep Disturbance 8a score change in subjects taking 50 mg of TruCBN when compared to the placebo group. Additionally, the researchers observed a U-shaped dose response curve that suggests doses as high as 100 mg and as low as 25 mg may have reduced effectiveness. This means that 50 mg is the optimal dose for aiding in sleep.

"The historical firsts encompassed in this study, especially discovering that CBN may have a U-shaped dose-response curve, have tremendous implications for formulating effective, natural sleep products for Americans. The findings especially highlight the importance of using the right dosage. For CBN, both too much (100 mg) and too little (25 mg) may have decreased effectiveness," explained Jeff Chen, Radicle Science cofounder and CEO in a press release.

"Our results pave the way for developing more effective sleep solutions, ultimately improving the quality of life for millions of people who struggle with sleep disturbances," said FloraWorks CEO and Cofounder Alleh Lindquist. "These findings bring needed clarity to the rapidly growing consumer demand for existing CBN products. Our TruCBN will be a new competitor in the global sleep aid market and marks a major milestone in building consumer trust and confidence in the therapeutic potential of cannabinoids."